IRLAB Therapeutics (IRLAB) Q4 2024 earnings summary

Executive summary

• Advanced a robust pipeline targeting all stages of Parkinson's and neurodegenerative diseases, with five first-in-class drug candidates in clinical and preclinical development and new strategic partnerships.

• Achieved key clinical milestones, including completion of patient enrollment in the Phase IIb study for pirepemat, positive Phase I results for IRL757, and preparations for mesdopetam Phase III.

• Secured significant external funding and partnerships, notably with The Michael J. Fox Foundation and MSRD/Otsuka, supporting clinical progress.

• CEO transition in August 2024, with Kristina Torfgård taking the helm and emphasizing innovation, collaboration, and growth.

Financial highlights

• Net sales for 2024 reached SEK 94.6 million, up from SEK 5.7 million in 2023, driven by collaboration and milestone payments.

• Operating loss narrowed to SEK -75.1 million from SEK -180.8 million year-over-year.

• Earnings per share improved to SEK -1.6 from SEK -3.43 year-over-year; net loss for the year was SEK -83.1 million.

• Cash and cash equivalents at year-end were SEK 66.9 million, with SEK 17 million as prepayments from partners.

• R&D costs totaled SEK 163.7 million, representing 87% of operating expenses.

Outlook and guidance

• Topline data from the Phase IIb study of pirepemat expected in Q1 2025.

• Phase III program initiation for mesdopetam planned, with ongoing business development and regulatory alignment in the US and Europe.

• IRL942 and IRL1117 projected to be Phase I ready in 2025; IRL757 development fully funded through Proof-of-Concept via partnership.

• Active pursuit of new licensing, partnership, and financing agreements to secure future funding.